
Annual report 2025
added 02-17-2026
Accuray Incorporated Revenue 2011-2026 | ARAY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Accuray Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 459 M | 447 M | 448 M | 430 M | 396 M | 383 M | 419 M | 405 M | 383 M | 399 M | 380 M | 369 M | 316 M | 409 M | 222 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 459 M | 222 M | 391 M |
Quarterly Revenue Accuray Incorporated
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 M | 93.9 M | - | 113 M | 116 M | 102 M | - | 101 M | 107 M | 104 M | - | 118 M | 115 M | 96.5 M | 211 M | 96.2 M | 116 M | 107 M | 224 M | 103 M | 97.5 M | 85.3 M | 97.5 M | 85.3 M | 98.8 M | 89.6 M | 98.8 M | 89.6 M | 102 M | 95.8 M | 114 M | 99.8 M | 100 M | 91 M | 191 M | 97.3 M | 87.5 M | 86.5 M | 87.5 M | 86.5 M | 109 M | 89.6 M | 109 M | 89.6 M | 98.2 M | 82.4 M | 98.2 M | 82.4 M | 93.6 M | 76.6 M | 93.6 M | 76.6 M | 77.8 M | 82.7 M | 77.8 M | 82.7 M | 106 M | 100 M | 106 M | 100 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 224 M | 76.6 M | 102 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
4 B | $ 176.57 | 5.81 % | $ 13.2 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.2 | 2.14 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
AxoGen
AXGN
|
225 M | $ 32.98 | 6.42 % | $ 1.52 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.21 | 4.2 % | $ 5.69 K | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
64 M | $ 24.38 | 2.52 % | $ 206 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.13 | 0.61 % | $ 259 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 91.75 | 1.9 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.12 | 1.48 % | $ 872 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.36 | -1.29 % | $ 126 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.62 | 2.46 % | $ 38.6 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.8 | 1.34 % | $ 351 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.36 | 5.18 % | $ 1.13 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.8 | 1.21 % | $ 47.8 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 53.19 | -2.25 % | $ 1.56 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.86 | 1.64 % | $ 1.13 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.54 | 2.25 % | $ 735 M | ||
|
Inogen
INGN
|
349 M | $ 6.75 | -0.81 % | $ 180 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.11 | 7.78 % | $ 18.8 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 87.21 | 2.42 % | $ 3.03 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.86 | 0.63 % | $ 372 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.66 | 0.49 % | $ 67.7 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 88.33 | 2.17 % | $ 114 B |